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many services has shifted to China, India, and other places. Both policy mak-
ers and the practitioners amongst us have to look at this issue through a wide
angle lens.
Today we have two respected practitioners of IP law. On my immediate
left is Kelly Gill, who is the department head of intellectual property group in
Toronto, and he is the national leader of Gowling and Henderson, and it is
Gowling, Lafleur and Henderson now, of their IP litigation national practice
group. Kelly was selected as one of the top 40 under 40 Canadian lawyers
about two years ago, and he has appeared in many, many cases in the country
and including acting for the Law Society of Upper Canada in a landmark
copyright infringement case. Our second speaker will be Michael Elmer,
partner of the U.S. IP law firm of Finnegan, Henderson, Farabow, Garrett,
and Dunner, and he is based in Palo Alto. And he has spent over 30 years in
the IP law field.
One of the things he has done is develop a global litigation base from
which he is going to share some views on where and how IEP litigants might
go about enforcing their rights. So we have two guides through the IP thicket,
and they are going to talk about the big picture on how practitioners go about
choosing the jurisdiction and which to enforce IEP law. So with that, Kelly?
CANADIAN SPEAKER
A. Kelly Gill*
I am going to cover three basic areas today. I would like to start off by
giving you a general idea of the Canadian patent landscape, to give you some
idea about who files patents in Canada, where these patent filers come from
geographically in the world, how much litigation goes on, and what type of
win rates are happening in Canada with respect to patent litigation. Then,
briefly, I am going to look at multi-jurisdictional litigation. Really, what I
want to do is just touch on it because Mike is going to give a much more in
depth look at worldwide patent litigation. But, I would like to just reinforce
the notion that patents, as with other intellectual property, are still territorial
A. Kelly Gill is Department Head of Gowling Lafleur Henderson LLP Intellectual Prop-
erty Group in Toronto and specializes in trademark, copyright, patent and misleading advertis-
ing litigation, including related rights and opinion work. Mr. Gill was selected as one of Can-
ada's top lawyers under the age of forty in December 2004. Mr. Gill's practice has brought
him before the Supreme Court of Canada, the Federal Court of Appeal, the Federal Court Trial
Division, the Ontario Court of Appeal, High Court and Divisional Court. Mr. Gill is an author
of The Canadian Law of Trade-Marks and Unfair Competition. Mr. Gill has sat on the edito-
rial boards of the Canadian Intellectual Property Review and Patent World (London).
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national rights and that different results and different facts can occur in dif-
ferent jurisdictions, leading to, of course, different results and different
strategies going forward to inform international patent holders. Finally, I
would like to cover something a little different and quite new in Canada, and
that is the impact of U.S. Patent law on Canadian patent litigation. I won't say
anything more on it until I actually get to it because prior to last month in a
decision of our Federal Court of Appeal, U.S. law had absolutely no impact
in Canada, but it has started to have some limited impact. Last year's statis-
tics for the top patent grantees in Canada show that six out of the top ten fil-
ers are actually U.S. based companies.' Included in the list are also a South
Korean, a Japanese, and a French-based company. 2 There is only one Cana-
dian company as a top ten patent grantee in Canada, and that is Nortel.3 Now,
you have to take into consideration, of course, given Nortel's fall from grace,
that these are granted patents and, therefore, there is a time lag from when
they actually filed the patents to when the patents were granted. So, you can
likely expect that Nortel would fall under this list in the next few years be-
cause the number of patents they filed has dropped dramatically.4 I should
have put a chart up given the last presentation showing the drop in the Amer-
ica price, what happened to Nortel and to most Canadians who own Nortel,
which most Canadians did one way or the other, but I won't because it is too
depressing for pretty much everybody, including myself.
The top filers of patents in Canada, a couple of points to glean from this
chart, again, six of the top ten filers in Canada are U.S. companies, two Ger-
man companies, a Japanese, one from Switzerland, absolutely no Canadian
company in the top ten for filing in their own country.5 You also note that the
group of patent filers and patent grantees are actually different, so the top ten
groups are not the same. The other thing to note - and we will come to it
later - is how many patents are actually being filed by presumably the largest
filers in Canada, Proctor & Gamble leading the list with 300 patents, the rest
all falling down to sort of 150 being a very large filer in Canada, 6 and when
we get to some of the U.S. statistics, you will see how this compares and it is
quite dramatic.
CAN. INTELLECTUAL PROP. OFF., ANNUAL REPORT 2003-2004, Table 12,
http://strategis.ic.gc.ca/sc-mrksv/cipo/corp/annualO304/reportO3O4-app3-e.html (last visited
Oct. 11, 2006).
2 Id.
3 Id.
4 See CAN. INTELLECTUAL PROP. OFF., ANNUAL REPORT 2004-2005, Table 12,
http://strategis.ic.gc.ca/sc-mrksv/cipo/corp/annualO405/reportO405-app3-e.html (last visited
Oct. 11, 2006) (showing Nortel fell out of the top ten the very next year).
5 ANNUAL REPORT 2003-2004, supra note 1 at Table 12.6 Id. at Table 11.
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Canadian patents issued by a country of applicant, you will see that the
United States far and away is the largest filer of patents in Canada: 17,000;
over 6,000 patents were granted to U.S. based companies.7 Canada, while it
is the second largest filer of patent applications in its own country, falls to
third in terms of the actual number of patents granted behind Japanese pat-
ents and Japanese companies filing patents.
8
And it is not that much greater even in terms of the applications than the
next five countries of origin for the patents. What's equally perhaps strange
or perplexing about this, if you look, for instance, at the Japanese numbers,
the applications filed is just over 2,600 with 1400 patents being granted from
that, whereas Canadians filed over 5,000 patents but, yet, only received about
1,200 patents.9 Of course, a patent application means absolutely nothing. It
gives no property rights. All it does is, in fact, disclose your invention to the
world so other people can use it, so we are looking in the vicinity of 4,000
applications that end up with no property rights. So the proportion of patents
actually granted to Canadian companies who file is relatively low compared
to other countries who file in the Canadian office.
If you look at the United States in terms of the top filers, you will see ab-
solutely of the top ten companies nine of them are completely different than
any of the top ten companies we just looked at from the Canadian Patent
Office.1° The only company that crosses both top ten lists, both in terms of
the United States and in terms of Canada, is Samsung. l" All the other ones in
this list do not show up in the Canadian top filing list. In addition, if you look
at the number of patents being filed, many people, of course, have heard
about the IBM strategy and how IBM leads in terms of filing patents in the
United States and has for many years with over 3,000,12 but compare that to
the chart we saw before with respect to Canada where the top filer in Cana-
dian is Proctor & Gamble who had 300 patents being filed. So a very signifi-
cant difference in the number of patents being filed by the top filers in the
two countries. Combine that with the fact the actual companies doing the
filing are completely different and you end up with a question as to what is
actually going on in terms of strategy for these companies in North America.
The other point to take from this slide is that for the U.S. market, again the
U.S. companies actually dominate the filing, and it is United States and Japa-
7 Id. at Table 14.
8 Id.
9 Id.
10 U.S. PATENT AND TRADEMARK OFF., CALENDAR YEAR 2004 PREIMINARY LIST OF Top
PATENTING ORGS., http://www.uspto.gov/web/offices/ac/ido/oeip/taf/top04cos.htm (last visited
Oct. 11, 2006).
1 Id.
12 Id.
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nese companies that are the top filers in the United States with the exception
of Samsung again.
All these statistics tend to raise more questions than they do answers be-
cause you would think in terms of the North American economy and the fact
that with the Free Trade Agreement and the North American Free Trade
Agreement, that there would be integration, that you will see a similar pattern
among the filing of applications and granted patents between the two coun-
tries, which you don't. So you would really have to, I think, dig further than
the statistics I have seen to find out in what areas these companies are filing
and why certain companies would be filing more in Canada or in another
sense not at all in Canada. And there really is no particular answer that I have
been able to find in looking over the companies, in terms of the manufactur-
ing sector that they are in, as to the strategy that is going on. In fact, I can't
even particularly figure out why the French company in Canada, one of the
top ten filers, is L'Oreal. It doesn't seem to make a lot of sense to me that
L'Oreal is a top ten filer in Canada, while no company like Lucent or Cisco
appears on the list. Again, more questions than answers.
The other interesting comparison that you can see from these charts re-
garding who is actually filing and obtaining patents in the United States by
country is that the United States itself has more U.S. patents than anyone else
in its own country.1 3 It outdoes Japan, Canada and the like, Canada being
way down on the list of filers.' 4 1 was interested to see the earlier statistics on
R & D spending in the respective countries because it showed Canada as
being eighth on the list,15 which kind of makes sense since Canada ends up
being eighth in terms of patents in the United States, until it turned out not to
be the top ten list of R&D countries. Canada was actually probably lower
than eighth in terms of spending. But one of the things to look at is the Japa-
nese, the German, Taiwanese, South Korean, the UK, and France all are well
ahead of the largest trading partner of the United States, Canada. 16 You
would think that Canada, with that trading status, and being geographically
right next to the country, would be one of the larger filers and obtainers of
patents, when it is not. The rule of thumb that often is used in comparisons
between the United States and Canada is the ten-fold rule of thumb - any-
thing in the United States is about ten times the size of Canada, with some
exceptions of course. See, somebody got it, and I don't even know what I was
saying, really.
13 U.S. PATENT AND TRADEMARK OFF., PATENTS BY COUNTRY, STATE, AND YEAR (2005),
http://www.uspto.gov/web/offices/ac/ido/oeip/taflcst-all.htm (last visited Oct. 11, 2006).
4 Id.
15 Id.
16 Id.
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But if you tip that rule of thumb, you would see that if you took how
many patents were actually obtained in Canada, Canada would be more in
the vicinity of around 13,000 patents in the United States, which would put it
as the third-ranked country in the United States. This would make a lot more
sense in terms of business, R & D, the market they are trying to protect; Ca-
nadians should be trying to protect the market they are most likely selling to,
but they are not.
The other point to glean from this chart and the earlier one is that, in fact,
Canadians obtain more patents in the United States than they do in Canada.
There were only about 1,300 you will recall from the earlier slide patents
being obtained by Canadians in Canada, whereas in the United States, it is in
the vicinity of 3,300.17 We have seen, at least in our practice, many Canadian
companies who do have international filing programs, which often choose to
file in the United States for patent protection and don't file in Canada. You
have to sometimes question whether that is the correct move on their part,
from a business perspective, or whether there is a real business interest in
doing that, in terms of saving costs, in terms of filing in Canada and using the
United States protection that they have gained as leverage to stop whatever
may be going on in Canada. And that may be an issue and maybe one of the
driving forces for it, or they may just not fear any competition in Canada for
the same product because of the smallness of the market compared to the
United States. The economies of scale make it less likely that somebody
would come in to Canada and infringe the patent when they can't do it in the
United States against the same patent holder, making it less cost effective to
obtain protection in both countries.
1 8
The other aspect to take from it is that, for Canadian companies there are
tens of thousands of patents being granted in the United States, inventions
being disclosed that are not protected in Canada.' 9 It is a literal gold mine of
technology that could be used by Canadian companies in Canada royalty free
without license, without any difficulty whatsoever.20 The only difficulty with
it all is to export any of that product or service would infringe the patents in
the United States, but they could take the technology that has been disclosed
in the U.S. Patent Office, as anybody could, and work it in the home country
of Canada. And there are literally tens of thousands of patents, inventions
that obviously have economic value that could be worked in Canada without
17 ANNUAL REPORT 2003-2004, supra note 1 at Table 14; PATENTS BY COUNTRY, STATE,
AND YEAR, supra note 13.
18 See Steven B. Garland & Jeremy E. Want, The Enforcement of Intellectual Property
Rights in Canada, http://strategis.ic.gc.ca/epic/intemetlinippd-dppi.nsf/en/ipOl4Ole.html (last
visited Oct. 12, 2006) (discussing the economics of patent prosecution in Canada).
19 Id.
20 Id.
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any repercussions, if you think about those repercussions as being a direct
injunction enforced upon them by a court, because the U.S. patents, of
course, have no impact in Canada directly. It would only be through business
leverage or market economics that would otherwise prohibit a Canadian
company from doing that.
That brings us to patent litigation in Canada, and I have not included this
on the slide, but here you will find about 100 patent cases being filed in Can-
ada every year.
Most patent cases in Canada are handled by our federal court.21 There are
no juries in the federal court permissible.22 Of the hundred or so actions filed
every year, you will find approximately ten, with the exception of 2005, go-
ing to trial.23 So there is a small base of actual actions to compare. You will
also note that most of the cases going to trial in terms of patent litigation are
pharmaceutical cases, 24 and that's because of our very robust Canadian ge-
neric industry25 that has done so well to actually increase the size of my firm
dramatically in terms of litigators. Without them you would see we would
only have about four patent cases a year at maximum, whereas with them we
are dealing with last year 15 cases, 14 of which were pharmaceutical.
Now, I always think of Canada as sort of a pro-patentee market, very
much like the United States, and if you are a patentee, you have a good
chance of success in Canada.26 You don't have to worry about the whims of
juries because jury trials aren't permitted if you go federally. Very unlikely
you are going to take a patent action in the provincial courts, even though
you could because it is limited in terms of jurisdiction, and then in the pro-
vincial court, you could choose a jury. But given most IP lawyers in Canada
have never appeared before a jury from their own fear, I doubt they would
21 FED. CT. OF CAN., AcTIvrrY SUMM. JAN. 1 TO DEC. 31, 2005, http://www.fctcf.gcca/
about/statistics/fcdec05_e.shtml (last visited Oct. 12, 2006) (showing statistics for patent
litigation in the Canadian Federal Court during 2005); see also FED. CT. OF CAN., STATISTICS,
http://www.fctcf.gc.ca/about/statistics/statistics-e.shtml (last visited Oct. 12, 2006) (The Fed-
eral Court's webpage has statistics on patent litigation dating back to 2000).
22 See Bob H. Sotiriadis & Alexandra Steele, Separate Trial on Claim Construction Or-
dered in Patent Infringement Case, 17-9 WORLD INTELLECTUAL PROPERTY REPORT 5, Publica-
tion 142.159 (2003), http://www.robic.conpublications/Pdf/142.159-BHS.pdf (last visited
Oct. 12, 2006) (mentioning how juries are not used in the Canadian Federal Court).
23 Gary T. Daniel, Strategies for Dealing with Infringements and Related Issues Outside
the United States- A Canadian Perspective, SJ055 ALI-ABA 163, 172 (2004).
24 Andrew Bernstein & Grant Worden, Sands Shift for Pharma Patents, AMERICAS
ENFORCEMENT Focus (2005), http://www.torys.com/publicationspdf/AR2005-35T.pdf (last
visited Oct. 15, 2006).
25 Ron J.T. Corbett, Impact of NAFTA and TRIPS on Intellectual Property Rights Protec-
tions in Canada and the United States, 6 NAFT'A: L. & Bus. REv. AM. 591, 616 (2000).
26 See M. Kent Ledwell, Why Should US Clients File in Canada?, GROWUNGS RESOURCE
CENTRE, (1999), http://www.gowlings.com/resources/publications.asp?pubid=107 (last visited
Oct. 10, 2006).
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ever do it themselves unless they were absolutely instructed by a client to do
it. So to my knowledge, there has never been a jury trial in a patent case in
Canada.27 Federal courts are judge only. So that was my notion, that it was
very pro-patent. But you will see from the stats as to actually what happened,
with the exception of 2001, where you see that three patents were found to be
infringed; the vast majority were found not infringed. In other words, the
patent owner lost one way or another. I haven't broken it down, but not in-
fringed is a loss, regardless of how you look at it, whether the patent was
held invalid and, therefore, not infringed or held valid but not infringed. Both
of those stats are indicated by the not infringed column.
Clearly from the stats of non-pharmaceutical trials, like these, which are
just outside the pharmaceutical area, patentees don't have a great success
ratio in the past five years or so in Canada. In terms of pharmaceutical ac-
tions, such actions in Canada for patents are generally, though not exclu-
sively, done under a different type of regulatory regime referred to as the
PMNOC Guidelines or regulations dealing with patented medicines. 28 While
we refer to these as regular patent trials, they are not done with live wit-
nesses.29 They are done on the basis of affidavit evidence, cross-
examinations outside of court and then presenting yourself in court for any
number of days to a judge with the written record.30 Prohibition is the equiva-
lent of an injunction.
No prohibition is the equivalent of not infringed: you are free to put out a
generic version of the drug. So looking at these stats, again, I was a little
surprised primarily because we represent the brand name, ethical manufac-
turers, in my firm, and I thought we had a better record. But obviously, we
don't, because the stats here are not much different than the non-
pharmaceutical. There is a slightly better success ratio, roughly 35 percent, as
compared to the 25 percent success ratio of the non-pharmaceuticals. 3' But as
you will hear from Mike, this is vastly different than the success ratio for a
patent holder in the United States. When you combine this with the cost of
27 William F. Heinze, U.S. or Canada for Patent Enforcement?, I/P UPDATES: NEWS AND
INFORMATION FOR INTELLECTUAL PROPERTY PRACTITIONERS, (2005), http://ip-updates.
blogspot.comI2005/02/us-or-canada-for-patent-enforcement.htm (last visited Oct. 10, 2006).
2 See Jamal Hejazi, Transfer Pricing Within the North American Pharmaceutical Indus-
try: Has There Been a Structural Shift in Risk?, INTERNATIONAL (2006),
http://www.gowlings.com/resources/PublicationPDFs/Hejazi-itpjO10602.pdf (last visited Oct.
10, 2006).
29 See William H. Richardson & Aaron M. Sawchuk, Canada: Effectively Managing a
Global Patent Litigation Strategy, MCCARTHY TETRAULT LLP (2006), http://www.mondaq.
com/article.asp?articleid=40820 (last visited Oct. 10, 2006).
30 See id.
31 See Evidence Number 51, STANDING COMMITTEE ON INDUSTRY, SCIENCE AND
TECHNOLOGY, 30 (2003), http://www.healthcoalition.ca/icjune4.pdf (last visited Oct. 15, 2006)
(noting that cases show that pharmaceutical patentees win between 63% to 37%).
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patent litigation in Canada, which pharmaceutical or not, you are looking at
somewhere in the vicinity of about a million dollars Canadian for the litiga-
tion, with a success ratio of 25 to 35 percent, you start to get a picture of why
there may only be ten patent trials a year for the whole country.
The other perhaps influencing factor of it relates back to the earlier statis-
tics I mentioned with respect to who dominates the Canadian patent land-
scape, that being U.S. based companies. If you have a U.S. based company
dominating and owning the rights in Canada and there is an infringement
situation going on, the better chance is that that infringement action is going
on across North America, if not in other jurisdictions around the world, but it
certainly will be happening in both the United States and Canada. What hap-
pens in those instances dictates, I think, what happens to the 90 percent of the
other cases that never go to trial, and that is, that the United States action
drives the Canadian action. The United States action will go to trial actually
much faster than the Canadian case.32 The market is obviously much more
important in the United States, and, therefore, whatever happens in the
United States, often from a business perspective in terms of leverage, will
ultimately dictate rule. That day in Canada there is often a settlement right
after the United States action has been decided, finally in court, and regard-
less of whether it is pro or not, and that often is the case even outside of the
United States. If you look at multi-jurisdictional litigation that we in Canada
have been involved in, because the Canadian court systems are slower than
many other jurisdictions, Canada will not be the first one to have a case
heard. We are often faced with, as litigators in Canada, doing patent actions
where a case has already been tried once, twice, sometimes three times be-
fore the Canadian trial is about to happen. And in some senses, that is excel-
lent because we already know what's going to happen. We already know
what the witnesses are going to say, and we can modify it. But in other cases,
everything has already been decided for us in advance.
I just wanted to give an example of that. This was a pharmaceutical case
for Bayer up against a generic in the UK and Canada,33 and there was an
equivalent action going on in the United States. 34 The UK action went to trial
in February of '94.35 The claims were held invalid on the basis of obvious-
32 See Intellectual Property and Innovation in the Knowledge-Based Economy, INDusTRY
CANADA (2005) http://strategis.ic.gc.ca/epic/intemet/inippd-dppi.nsf/en/ip01410e.html (last
visited Oct. 15, 2006) (stating that the United States has created new institutions in order to
make intellectual property litigation faster).
33 Bayer A.G. v. Norton Healthcare Limited (unreported, 1994); Bayer Aktiengesell-
schaft v. Apotex Inc., [1995] 60 C.P.R. (3d) 58 (Ont. Gen. Div.), affd, [1998] 82 C.P.R. (3d)
526 (Ont. Gen. Div.).
34 Bayer A.G. v. Elan Pharmaceutical Research Corp., 64 F. Supp. 2d (N.D.Ga. 1999).
35 Bayer A.G. v. Norton Healthcare Limited, supra note 33.
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ness. 36 The court there said that it was absolutely obvious to put this drug
within a capsule that was bitable, and there was absolutely no inventive step
to it.37 Unlike the scenarios I gave you before, the company decided to pur-
sue the action in Canada, regardless of the outcome in the UK, and there the
patent was held valid and infringed.38 The court specifically stated that the
obviousness test in the UK for whether the invention was obvious or not,
which they refer to it as a worth-a-try test, the inventor going to it and look-
ing at what they potentially try and say it is worth a try to try to put those two
things together and do it,39 was not the applicable law in Canada. n° Therefore,
the patent was not obvious, and, in fact, it was valid and infringed. 4' That
particular case, even though it was decided in 1995, I thought it was relevant
because the reference for damages is going ahead in a couple of months and
will likely end up being one of the largest patent damage awards in Canadian
history.
The third point I wanted to bring out was with respect to a very recent oil
and gas case, with respect to two companies, one based in the United States,
the patent holder, Varco. Pason is a candy based company with a North
American market, Varco the patent holder in both countries. There is litiga-
tion going on in both countries, suing on identical patents that were issued
from both the United States and Canadian Patent Offices.42 But what we did
in Canada is that we actually pled a novel defense, certainly never done be-
fore. In the United States, there is what is referred to as fraud on the Patent
Office; that will invalidate a U.S. Patent.43 An inventor-applicant and their
representatives in the United States are required to disclose to the U.S. Patent
Office any relevant prior art they have within their knowledge when they are
applying."a In Canada, there is no such obligation; an applicant in Canada
could know of relevant prior art and does not have to disclose it to the Patent
Office at all.45 What we did in this case was that we alleged that the appli-
36 Bayer A.G. v. Norton Healthcare Limited & Bayer Aktiengesellschaft v. Apotex Inc.,
supra note 33.
37 Bayer A.G. v. Norton Healthcare Limited, supra note 33.
38 Bayer Aktiengesellschaft v. Apotex Inc., supra note 33.
39 id.
40 Id.
41 Id.
42 Varco v. Pason Systems USA Corp. 436 F. 3d 1368 (Fed. Cir. 2006); Pason Systems
Corp. v. Varco Canada Ltd., [2006] F.C.A. 100.
4 See generally Arnold B. Silverman, Disclosing Prior Art to the U.S. Patent and Trade-
mark Office, 49 JOM 7, 74 (1997) (explaining that no patent will be granted on an application
when fraud was attempted or practiced on United States Patent and Trademark Office), avail-
able at http://www.tms.org/pubs/joumals/JOM/matters/matters-9707.html.
44 id.
45 See generally Donald M. Cameron and Ogilvy Renault, Patent Law Primer,
JURISDICTION, http://www.jurisdiction.com/patprim.htm (last visited Oct. 15, 2006) (Stating
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cant, the U.S. inventor, failed to disclose certain prior art in the United States
contrary to his obligations, that the Canadian examiner later on asked for a
copy of the patent cited in the United States, and the applicant provided ex-
actly that to the Canadian examiner, the prior art cited in the United States.46
What we pled was that was off side the Canadian act because it was not a
good faith response to the Canadian examiner since there was never a good
faith disclosure of all the prior art in the United States, and if they had actu-
ally complied with their good faith requirements in the United States and
disclosed all the prior art, they would have had to disclose certain prior art
that then would have come to the attention of the Canadian examiner.47
What's interesting is, of course, the Plaintiff, and we are representing the
Defendant in this, came up with this great defense and was struck by the fed-
eral court immediately by saying there was no such cause of action to invali-
date a patent in Canada. 48 We appealed that. The Federal Court Trial Divi-
sion agreed without saying much other than the original hearing officer was
completely correct, and there was no fraud on the Patent Office, invalidity
defense in Canada available at all, and what happens in the states is what
happens in the states.49 Last month the Federal Court of Appeals disagreed
with both courts below and said that it was a completely arguable defense
and that the lack of disclosure to the U.S. Patent Office could constitute a
lack of good faith response to the Canadian examiner when providing that
prior art that actually was before the U.S. PTO.50 This requires us, then, in
Canada, proving that the prior art should have been cited to the U.S. Patent
Office, and then, of course, that it should have been cited to Canada.
DR. KING: We are going to have to wind it up.
MR. GILL: Exactly. Thank you.
that there is generally no obligation to disclose prior art to the Canadian Patent Office except
when there is a statutory obligation to provide prior art which is available to other Patent Of-
fices, if requested).
46 Varco v. Pason Sys. USA Corp., supra note 42.
47 Varco Appellee Br. 2005 U.S. Fed. Cir. Briefs 1136, Mar. 30, 2005.
48 Id.
49 Varco v. Pason Sys. USA Corp., supra note 42.
50 Id. at 1368
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